Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches in dermatomyositis and
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care
Analysis of 187 audited patient charts reveals persistent operational barriers remain common for patients with large B-cell lymphoma (LBCL), reinforcing
Despite incremental gains in awareness and prescribing, most launch metrics continue to trail recent rheumatology benchmarks, underscoring both the challenges
Nephrologists now prioritize SGLT2 inhibitors for kidney protection over glycemic control, while one-third report no perceived benefit of GLP-1s in
Despite expanding biologic use, nearly 60% of lupus patients report high disease activity, while rising costs and treatment complexity continue
Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: EXTON, PA, April
High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a
On World Hemophilia Day 2026, Spherix Global Insights announces the publication of data revealing early but evolving uptake across novel
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients, increasing competitive switching, and a
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake.
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR
